We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Avandia suffers further setback.
- Authors
Houlton, Sarah
- Abstract
The article announces the decision of Prime Therapeutics and HealthSpan Pharmacy to delist GlaxoSmithKline's antidiabetes drug Avandia in the U.S. The drug will no longer be given to patients covered by the two pharmacy benefit management companies. According to Prime Therapeutics, since a meta-analysis claiming Avandia causes cardiovascular problems was published in May 2007, it has seen a 58 percent decline in the drug's use. The U.S. Department of Veteran Affairs had already decided to remove the drug from its formulary because of the cardiovascular risks it posed.
- Subjects
UNITED States; DRUG side effects; PRIME Therapeutics LLC; HEALTHSPAN Pharmacy (Company); GLAXOSMITHKLINE; UNITED States. Dept. of Veterans Affairs; TREATMENT of diabetes
- Publication
Chemistry & Industry, 2007, Issue 24, p7
- ISSN
0009-3068
- Publication type
Article